TORONTO, Jan. 23,
2024 /CNW/ - Greenbrook TMS Inc. (NASDAQ: GBNH)
("Greenbrook" or the "Company") today announced that
it has appointed Ms. Juliana Elstad
to the Company's board of directors as an independent director,
effective immediately. Ms. Elstad has also been appointed to the
Company's Governance and Nominating Committee.
Juliana Elstad is a CEO,
entrepreneur, and advisor with over 20 years of experience bringing
medical innovation to patients and delivering success in small
startup to multi-billion-dollar environments. She has a proven
track record of creating, growing, and leading medical technology
organizations with a focus on building dynamic cultures and
mentoring high-potential leaders. Ms. Elstad is currently the
president and CEO of Vibrato Medical, a medical device company
developing a novel non-invasive technology for treatment of Chronic
Limb Threatening Ischemia and Peripheral Arterial Disease. Prior to
Vibrato, Ms. Elstad served as CEO of Impleo Medical, a medtech
company recognized as one of the world's Top 50 most innovative
startups in 2018; founder of Elstad Medical, advisory firm to
medtech CEOs and boards; EVP of business development at Intelect
Medical (acquired by Boston Scientific); and led business
development efforts at Medtronic, Inc. as well as coordinated
strategic planning, performed market analyses for new therapies,
and led cross-functional committees. Ms. Elstad is currently a
member of the board of directors of AdvaMed, the world's largest
medtech trade association, where she provides strategic oversight
to the organization and prioritization of its policy goals.
About Greenbrook TMS
Inc.
Operating through 130 Company-operated treatment centers,
Greenbrook is a leading provider of Transcranial Magnetic
Stimulation ("TMS") therapy and Spravato®
(esketamine nasal spray), FDA-cleared, non-invasive therapies for
the treatment of Major Depressive Disorder ("MDD") and other
mental health disorders, in the United
States. TMS therapy provides local electromagnetic
stimulation to specific brain regions known to be directly
associated with mood regulation. Spravato® is offered to
treat adults with treatment-resistant depression and depressive
symptoms in adults with MDD with suicidal thoughts or actions.
Greenbrook has provided more than 1.3 million treatments to over
40,000 patients struggling with depression.
View original
content:https://www.prnewswire.com/news-releases/greenbrook-tms-announces-director-appointment-302042529.html
SOURCE Greenbrook TMS Inc.